-
Aptorum To Start Testing SACT-1 In Neuroblastoma Patients
Wednesday, September 15, 2021 - 9:26am | 233Read More...The FDA has signed off Aptorum Group Limited's (NASDAQ: APM) IND application to initiate clinical trials of SACT-1 for neuroblastoma. The IND-opening trial is a bioavailability/food effect study that will take four months to complete. The bioavailability/food effect study aims...
-
BeiGene's Pediatric Tumor Drug Scores Conditional Approval In China
Tuesday, August 17, 2021 - 10:09am | 213Read More...The China National Medical Products Administration (NMPA) granted conditional approval for BeiGene Ltd (NASDAQ: BGNE) - EUSA Pharma's (UK) Qarziba (dinutuximab beta) in high-risk neuroblastoma patients. The approval comes for patients aged 12 months and above...
-
Y-mAbs Therapeutics Raises $100M Via Equity To Fund Commercial Rollout Of Neuroblastoma Med
Thursday, February 18, 2021 - 6:20am | 377Read More...Y-mAbs Therapeutics Inc (NASDAQ: YMAB) priced its public offering of 2.4 million common shares at $41 per share, for gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 365,853 shares. The offering is expected to close...
-
Why Shares of Ignyta Are Trading Higher
Monday, December 29, 2014 - 10:07am | 234Read More...Shares of Ignyta Inc (NASDAQ: RXDX) were trading higher by more than 6 percent during Monday's pre-market session after the company announced that the FDA designated its entrectinib, a lead product candidate an Orphan Drug for the treatment of neuroblastoma. The FDA grants Orphan Drug...
